Cases & Deals

Puma Biotechnology asserts patent infringement claims under Hatch-Waxman Act related to Nerlynx® against Sandoz

Clients Puma Biotechnology, Inc.

Jones Day is representing Puma Biotechnology, Inc. in a Hatch-Waxman patent infringement action against Sandoz relating to Sandoz's submission of an Abbreviated New Drug Application to the FDA seeking approval of a purported generic version of Nerlynx® (neratinib) tablets.

Puma Biotechnology, Inc., et al. v. Sandoz, Inc., No. 1-21-cv-19918 (D.N.J.)